Sugi Predict

Sugi Predict / Compounds / SCHEMBL29599104

SCHEMBL29599104

SCHEMBL29599104

CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O

nearest known ligand 0.65

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ NPY1R P25929 1/20 0.65
▸ NPY2R P49146 1/20 0.65
▸ NPY4R P50391 1/20 0.65
▸ NPY5R Q15761 1/20 0.65
▸ CXCR4 P61073 7/20 0.64
▸ GLP1R P43220 3/20 0.62
▸ PRLHR P49683 4/20 0.61
▸ KISS1R Q969F8 2/20 0.59
▸ CALCA P06881 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30398408 0.89 NPY1R (0.65) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL30494418 0.88 NPY2R (0.67) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL30658333 0.88 NPY2R (0.73) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL31441008 0.88 CXCR4 (0.63) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL31683347 0.88 NPY2R (0.71) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL29598775 0.87 NMBR (0.62) NPY1RNPY2RNPY4RNPY5RGLP1R
SCHEMBL30658307 0.87 NPY1R (0.65) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL30658328 0.87 NPY2R (0.74) NPY1RNPY2RNPY4RNPY5RGLP1R
SCHEMBL30495767 0.87 NPY1R (0.69) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL30607423 0.87 NPY2R (0.69) NPY1RNPY2RNPY4RNPY5RCXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179130-A1 METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS ON TARGET THERAPEUTICS LLC 2025-06-05 — — US disclosed
US-12060397-B2 Soluble lipidated ligand agents for treating eye inflammation TUFTS MEDICAL CENTER (US) 2024-08-13 — — US disclosed
US-11421223-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. (US) 2022-08-23 — — US disclosed
US-20220135633-A1 METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS ON TARGET THERAPEUTICS LLC 2022-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135633-A1 METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS LDLR, HDLBP, LIPG NPY1R 3820/4885NPY2R 3500/4885NPY4R 3663/4885
US-20250179130-A1 METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS LDLR, HDLBP, LIPG NPY1R 3820/4885NPY2R 3500/4885NPY4R 3663/4885
US-12060397-B2 Soluble lipidated ligand agents for treating eye inflammation LIPG, CD40, LDLR NPY1R 3330/4885NPY2R 2910/4885NPY4R 2901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback